SlideShare a Scribd company logo
1 of 5
Download to read offline
Introducing: Green Fluorescent Nanoparticle-labeled human Mesenchymal Stem Cells

  These cells add to our fluorescein, rhodamine and GFP-expressing MSCs and offer
  an alternative fluorescent MSCs with the following properties:
       •Generated by chemical transfection of CdSe/ZnS nanoparticles, 100 nm in
       diameter
       •Strong fluorescent signal (Exmax= 515 nm; Emissionmax= 520-550 nm)
       detectable by standard FITC filters.
       •Retains fluorescence through growth or differentiation into chondrogenic,
       adipogenic or osteogenic lineages.
       •Possible indicator of endoplasmic processing within MSCs
       •Fluorescence is detectable in three successive passages and diminishes with
       passage.
       •Useful in tracking and imaging investigations based on MSCs
FITC analysis of cells during second passage following transfection. Image obtaining using FITC
filter on Olympus CKX41 microscope at 200 X equipped with a Retiga 2000 digital camera and
Q-Capture software program. Scale bar is 25 micrometers.
FITC analysis of cells during third passage following transfection. Image obtaining using FITC
filter on Olympus CKX41 microscope at 200 X equipped with a Retiga 2000 digital camera and Q-
Capture software program. Scale bar is 25 micrometers. Note that this culture is at higher cell
density than the previous image.
FITC analysis of cells during fourth passage following transfection. Image obtaining using FITC
filter on Olympus CKX41 microscope at 200 X equipped with a Retiga 2000 digital camera and Q-
Capture software program. Scale bar is 25 micrometers. Fluorescent nanoparticles are less
prevalent within the cytoplasm than earlier passages.
Osteogenic differentiation of Grn-fluorescent nanoparticle-labeled MSCs. Image obtaining using phase
contrast Olympus CKX41 microscope at 100 X equipped with a Retiga 2000 digital camera and Q-Capture
Pro software program. Scale bar is 25 micrometers. Note the presence of mineral deposits indicating
differentiation into osteoblasts. Chondrogenic and adipogenic differentiation was also apparent .

More Related Content

More from Pete Shuster

Biopharma musculoskeletal disorders_draft 6-30-2013 jm edits
Biopharma musculoskeletal disorders_draft 6-30-2013 jm editsBiopharma musculoskeletal disorders_draft 6-30-2013 jm edits
Biopharma musculoskeletal disorders_draft 6-30-2013 jm edits
Pete Shuster
 
Cell based assays presentation V2_03_2012
Cell based assays presentation V2_03_2012Cell based assays presentation V2_03_2012
Cell based assays presentation V2_03_2012
Pete Shuster
 

More from Pete Shuster (18)

Neuromics base presentation 2020
Neuromics base presentation 2020Neuromics base presentation 2020
Neuromics base presentation 2020
 
Neuromics base presentation 2019
Neuromics base presentation 2019Neuromics base presentation 2019
Neuromics base presentation 2019
 
Human blood brain barrier
Human blood brain barrierHuman blood brain barrier
Human blood brain barrier
 
"Bedside to Bench" in Drug Discovery
"Bedside to Bench" in Drug Discovery"Bedside to Bench" in Drug Discovery
"Bedside to Bench" in Drug Discovery
 
Poster sot 2015_am_final
Poster sot 2015_am_finalPoster sot 2015_am_final
Poster sot 2015_am_final
 
CELL-a-brate-Knowing Your Assays
CELL-a-brate-Knowing Your AssaysCELL-a-brate-Knowing Your Assays
CELL-a-brate-Knowing Your Assays
 
Regenerative Medicine Industry Outlook 2014
Regenerative Medicine Industry Outlook 2014Regenerative Medicine Industry Outlook 2014
Regenerative Medicine Industry Outlook 2014
 
Vitro Biopharma-Business & technical overview 12 9-13
Vitro Biopharma-Business & technical overview 12 9-13Vitro Biopharma-Business & technical overview 12 9-13
Vitro Biopharma-Business & technical overview 12 9-13
 
Neuron Glial Interactions
Neuron Glial InteractionsNeuron Glial Interactions
Neuron Glial Interactions
 
Optimized Protocol for Sorting Cells
Optimized Protocol for Sorting CellsOptimized Protocol for Sorting Cells
Optimized Protocol for Sorting Cells
 
Biopharma musculoskeletal disorders_draft 6-30-2013 jm edits
Biopharma musculoskeletal disorders_draft 6-30-2013 jm editsBiopharma musculoskeletal disorders_draft 6-30-2013 jm edits
Biopharma musculoskeletal disorders_draft 6-30-2013 jm edits
 
Biopharma musculoskeletal disorders_4-30-2013
Biopharma musculoskeletal disorders_4-30-2013Biopharma musculoskeletal disorders_4-30-2013
Biopharma musculoskeletal disorders_4-30-2013
 
Cell based assays presentation v3_03_2012
Cell based assays presentation v3_03_2012Cell based assays presentation v3_03_2012
Cell based assays presentation v3_03_2012
 
Cell based assays presentation V2_03_2012
Cell based assays presentation V2_03_2012Cell based assays presentation V2_03_2012
Cell based assays presentation V2_03_2012
 
Essen bioscience neuromics 9_17_12
Essen bioscience neuromics 9_17_12Essen bioscience neuromics 9_17_12
Essen bioscience neuromics 9_17_12
 
Arun A Neuromics Hca Hts Overview V3 04 26 2011
Arun A Neuromics Hca Hts Overview V3 04 26 2011Arun A Neuromics Hca Hts Overview V3 04 26 2011
Arun A Neuromics Hca Hts Overview V3 04 26 2011
 
Neuromics Presentation V4
Neuromics Presentation V4Neuromics Presentation V4
Neuromics Presentation V4
 
Apoptosis
ApoptosisApoptosis
Apoptosis
 

Recently uploaded

Structuring Teams and Portfolios for Success
Structuring Teams and Portfolios for SuccessStructuring Teams and Portfolios for Success
Structuring Teams and Portfolios for Success
UXDXConf
 

Recently uploaded (20)

The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdfThe Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
 
How Red Hat Uses FDO in Device Lifecycle _ Costin and Vitaliy at Red Hat.pdf
How Red Hat Uses FDO in Device Lifecycle _ Costin and Vitaliy at Red Hat.pdfHow Red Hat Uses FDO in Device Lifecycle _ Costin and Vitaliy at Red Hat.pdf
How Red Hat Uses FDO in Device Lifecycle _ Costin and Vitaliy at Red Hat.pdf
 
Microsoft CSP Briefing Pre-Engagement - Questionnaire
Microsoft CSP Briefing Pre-Engagement - QuestionnaireMicrosoft CSP Briefing Pre-Engagement - Questionnaire
Microsoft CSP Briefing Pre-Engagement - Questionnaire
 
Intro in Product Management - Коротко про професію продакт менеджера
Intro in Product Management - Коротко про професію продакт менеджераIntro in Product Management - Коротко про професію продакт менеджера
Intro in Product Management - Коротко про професію продакт менеджера
 
Syngulon - Selection technology May 2024.pdf
Syngulon - Selection technology May 2024.pdfSyngulon - Selection technology May 2024.pdf
Syngulon - Selection technology May 2024.pdf
 
Free and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
Free and Effective: Making Flows Publicly Accessible, Yumi IbrahimzadeFree and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
Free and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
 
Easier, Faster, and More Powerful – Notes Document Properties Reimagined
Easier, Faster, and More Powerful – Notes Document Properties ReimaginedEasier, Faster, and More Powerful – Notes Document Properties Reimagined
Easier, Faster, and More Powerful – Notes Document Properties Reimagined
 
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdfSimplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
 
Demystifying gRPC in .Net by John Staveley
Demystifying gRPC in .Net by John StaveleyDemystifying gRPC in .Net by John Staveley
Demystifying gRPC in .Net by John Staveley
 
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
 
The Metaverse: Are We There Yet?
The  Metaverse:    Are   We  There  Yet?The  Metaverse:    Are   We  There  Yet?
The Metaverse: Are We There Yet?
 
How we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdfHow we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdf
 
Using IESVE for Room Loads Analysis - UK & Ireland
Using IESVE for Room Loads Analysis - UK & IrelandUsing IESVE for Room Loads Analysis - UK & Ireland
Using IESVE for Room Loads Analysis - UK & Ireland
 
What's New in Teams Calling, Meetings and Devices April 2024
What's New in Teams Calling, Meetings and Devices April 2024What's New in Teams Calling, Meetings and Devices April 2024
What's New in Teams Calling, Meetings and Devices April 2024
 
Structuring Teams and Portfolios for Success
Structuring Teams and Portfolios for SuccessStructuring Teams and Portfolios for Success
Structuring Teams and Portfolios for Success
 
AI presentation and introduction - Retrieval Augmented Generation RAG 101
AI presentation and introduction - Retrieval Augmented Generation RAG 101AI presentation and introduction - Retrieval Augmented Generation RAG 101
AI presentation and introduction - Retrieval Augmented Generation RAG 101
 
Designing for Hardware Accessibility at Comcast
Designing for Hardware Accessibility at ComcastDesigning for Hardware Accessibility at Comcast
Designing for Hardware Accessibility at Comcast
 
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdfLinux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
 
ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...
ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...
ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...
 
Powerful Start- the Key to Project Success, Barbara Laskowska
Powerful Start- the Key to Project Success, Barbara LaskowskaPowerful Start- the Key to Project Success, Barbara Laskowska
Powerful Start- the Key to Project Success, Barbara Laskowska
 

Human mesenchymal stem cells green fluorescent nanoparticle-labeled sc00-a4np technical information

  • 1. Introducing: Green Fluorescent Nanoparticle-labeled human Mesenchymal Stem Cells These cells add to our fluorescein, rhodamine and GFP-expressing MSCs and offer an alternative fluorescent MSCs with the following properties: •Generated by chemical transfection of CdSe/ZnS nanoparticles, 100 nm in diameter •Strong fluorescent signal (Exmax= 515 nm; Emissionmax= 520-550 nm) detectable by standard FITC filters. •Retains fluorescence through growth or differentiation into chondrogenic, adipogenic or osteogenic lineages. •Possible indicator of endoplasmic processing within MSCs •Fluorescence is detectable in three successive passages and diminishes with passage. •Useful in tracking and imaging investigations based on MSCs
  • 2. FITC analysis of cells during second passage following transfection. Image obtaining using FITC filter on Olympus CKX41 microscope at 200 X equipped with a Retiga 2000 digital camera and Q-Capture software program. Scale bar is 25 micrometers.
  • 3. FITC analysis of cells during third passage following transfection. Image obtaining using FITC filter on Olympus CKX41 microscope at 200 X equipped with a Retiga 2000 digital camera and Q- Capture software program. Scale bar is 25 micrometers. Note that this culture is at higher cell density than the previous image.
  • 4. FITC analysis of cells during fourth passage following transfection. Image obtaining using FITC filter on Olympus CKX41 microscope at 200 X equipped with a Retiga 2000 digital camera and Q- Capture software program. Scale bar is 25 micrometers. Fluorescent nanoparticles are less prevalent within the cytoplasm than earlier passages.
  • 5. Osteogenic differentiation of Grn-fluorescent nanoparticle-labeled MSCs. Image obtaining using phase contrast Olympus CKX41 microscope at 100 X equipped with a Retiga 2000 digital camera and Q-Capture Pro software program. Scale bar is 25 micrometers. Note the presence of mineral deposits indicating differentiation into osteoblasts. Chondrogenic and adipogenic differentiation was also apparent .